Life and Medical Sciences
Yazarlar: Tuğba GÜLER SÖNMEZ, İzzet FİDANCI, Duygu AYHAN BAŞER, Hilal AKSOY, Duygu YENGİL TACİ, Mustafa CANKURTARAN
Konular:-
DOI:10.54584/lms.2022.10
Anahtar Kelimeler:COVID-19,Pandemic,Disease follow-up,Hospitalization time.
Özet: In this study, it was aimed to examine the follow-ups of patients diagnosed with COVID-19 during the pandemic process and to evaluate the relationship between the symptoms/disease characteristics of the individuals and their prognosis. The study was completed by retrospectively accessing the patient data with a diagnosis of COVID-19 between 01.04.2020 and 01.02.2021 using the archive scanning method. A total of 438 COVID-19 patients were included in the study. The study was completed by reaching the information questioned in the follow-up of the patients during the COVID-19 disease processes, information on the symptoms/disease characteristics and disease prognoses. Of the patients diagnosed with COVID-19, 49.3% were female and 50.7% were male. The hospitalization rate of the patients was found to be 12.3%. Hospitalization times of patients with cardiovascular disease, diabetes mellitus and respiratory system disease were found to be statistically significantly longer (p<0.001; p<0.001; p=0.045, respectively). There is a difference between the length of hospital stay of those with and without other chronic diseases (p=0.043). Hospitalization times were found to be significantly reduced in those using anticoagulants, steroids, and antibiotics. There was no difference between pneumococcal and influenza vaccination status and hospital stay. In this study, during the COVID-19 pandemic period, many parameters were examined in the follow-up of patients and conditions that could be related to the disease prognosis were evaluated. In the light of this information, it will be ensured that the prognosis of the people who will get COVID-19 disease will be predicted and the conditions that should be considered in the treatment and follow-up will be taken into consideration.